of the contents throughout a period of about 6–10 hours. This capsule is equivalent to one tablet of 5 mgm. potency taken three times a day. * * * Warning * * * Caution: Federal law prohibits * * * Supplied by Physicians Drug & Supply Co. Philadelphia, Pa."

LIBELED: 7–24–57, E. Dist. Pa.

CHARGE: 501(c)—the quality of the article, when shipped, fell below that which it was represented to possess since the active ingredient was not gradually released over a 6–10 hour period but instead was released in a much shorter time; and 502(a)—the label statements which represented that the active ingredient was gradually released over a 6–10 hour period and that 1 capsule of the article was equivalent to 1 tablet of 5 mgm. potency taken three times a day were false and misleading as applied to the article, since the active ingredient was released in less than a 6-hour period and since 1 capsule of the article was not equivalent to 1 tablet of 5 mgm. potency taken three times a day.

DISPOSITION: 9–12–57. Default—destruction.

5490. Digitoxin tablets. (F.D.C. No. 40298. S. Nos. 68–386/88 M, 68–390 M, 68–392 M.)

QUANTITY: 15 ctns., 12 100-tablet btls. each; 1 drum of 66,400 tablets and 1 drum of 99,800 tablets; 13,500 tablets in 100-tablet btls.; and 1 ctn. containing 19 1,000-tablet btls., at New York, N.Y., in possession of Park Drug Co., Inc.

SHIPPED: The tablets were prepared from digitoxin powder shipped between Oct. 1954 and Nov. 1956, from Paris, France.

LABEL IN PART: (Btls. and drums) "Digitoxin Tablets * * * 0.1 mg. [or "0.2 mg."]."

RESULTS OF INVESTIGATION: Examination showed that the tablets contained not more than 82.6 percent of the declared amount of digitoxin.

LIBELED: 6–5–57, S. Dist. N.Y.

CHARGE: 501(b)—the strength of the article, while held for sale, differed from the standard for digitoxin tablets set forth in the United States Pharmacopeia since the article contained less than 90 percent of the labeled amount of digitoxin, the minimum permitted by the standard.

DISPOSITION: 10–17–57. Default—destruction.

5491. Digitoxin tablets. (F.D.C. No. 40202. S. Nos. 62–918/9 M.)

QUANTITY: 58,400 tablets in 100-tablet btls. and 227,000 tablets in 1,000-tablet btls. at South Hackensack, N.J.

SHIPPED: Digitoxin powder was shipped on 5–7–56, from New York, N.Y.

LABEL IN PART: (Btls.) "Digitoxin U.S.P. 0.1 mg."

RESULTS OF INVESTIGATION: The tablets were prepared from the digitoxin powder shipped as described above.

Examination showed that the 58,400-tablet lot and the 227,000-tablet lot contained not more than 79.2 percent and 82.3 percent, respectively, of the declared amount of digitoxin.

LIBELED: 5–15–57, Dist. N.J.

CHARGE: 501(b)—the strength of the article, while held for sale, differed from the standard for digitoxin tablets set forth in the United States Pharmacopeia since the article contained less than 90 percent of the labeled amount of digitoxin.

DISPOSITION: 9-19-57. Default—destruction.

5492. Rythrogen. (F.D.C. No. 40398. S. No. 53-744 M.)

QUANTITY: 93 10-cc. vials at Dallas, Tex.

SHIPPED: 4-4-57 and 6-13-57, from Saratoga Springs, N.Y., by G. F. Harvey Co.

RESULTS OF INVESTIGATION: Examination showed that the article contained less than the declared amount of thiamine hydrochloride.

LIBELED: 8-1-57, N. Dist. Tex.

CHARGE: 501(c)—the strength of the article, when shipped, differed from that which it was represented to possess, namely, 4.5 mg. per cubic centimeter of thiamine hydrochloride; and 502(a)—the label statement "Each cc Contains * * * Thiamine Hydrochloride 4.5 mg." was false and misleading.

DISPOSITION: 9-3-57. Default—destruction.

5493. Pep-Ti-Kon. (F.D.C. No. 40410. S. No. 44-189 M.)

QUANTITY: 96 8-oz. btls. at Forrest City, Ark.

SHIPPED: 5-2-57, from Memphis, Tenn., by Berjon Co.

LABEL IN PART: "Blood-building Tonic * * * Pep-Ti-Kon."

RESULTS OF INVESTIGATION: Examination showed that the article contained 65 percent of the labeled amount of riboflavin.

LIBELED: 8-9-57, E. Dist. Ark.

CHARGE: 501(c)—the strength of the article, when shipped, differed from that which it was represented to possess, namely, 3.0 mg. per fluid ounce; and 502(a)—the label statement "Each fluid ounce provides: * * * vitamin B_2 (Riboflavin) 3.0 Mg." was false and misleading.

DISPOSITION: 9-11-57. Default—destruction.

DRUGS ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS*

5494. Nulsar. (Inj. No. 309.)

COMPLAINT FOR INJUNCTION FILED: 4-25-57, E. Dist. Mich., against Appletone Drugs, Inc., and Appletone Drug Laboratories, Inc., of Detroit, Mich., and Samuel Krone, president of the corporations and owner of the businesses operated under the names of Appletone Drugs and Nulsar Drug Laboratories, at Detroit, Mich.

LABEL IN PART: (Ctn.) "Nulsar-6 Special Tablets * * * For each full ounce of the enclosed product, the following ingredients are included: Powdered extracts of cattle organs in the following manner: Brain substance 2 grains Suprarenal substance ½ grain Desiccated liver 20 grains Hemoglobin 5 grains Gastric mucin 4 grains also: Ferrous gluconate 1 grain Pure dehydrated cream and milk containing not less than 53% up to 60% milk fat at the time of manufacture 325 grains Powdered cocoa, flavoring, sucrose, preservative, added."

*See also Nos. 5481, 5482, 5484, 5485, 5487-5489, 5492, 5493.